

Temporal Variability of Urinary Phthalate Metabolite Levels in Men of Reproductive Age

Russ Hauser, John D. Meeker, Sohee Park, Manori J. Silva,
and Antonia M. Calafat

doi:10.1289/ehp.7212 (available at <http://dx.doi.org/>)

Online 16 August 2004



“Temporal Variability of Urinary Phthalate Metabolite Levels in Men of Reproductive Age”

Russ Hauser^{a,b}, John D. Meeker^a, Sohee Park^c, Manori J. Silva^d, Antonia M. Calafat^d.

^a Department of Environmental Health, Harvard School of Public Health, Boston, MA.

^b Vincent Memorial Obstetrics & Gynecology Service, Andrology Laboratory and In Vitro Fertilization Unit, Massachusetts General Hospital, Boston, MA 02114.

^c Department of Biostatistics, Harvard School of Public Health, Boston, MA.

^d National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA.

Correspondence should be directed to:

Russ Hauser MD, ScD, MPH

Harvard School of Public Health

Department of Environmental Health

Occupational Health Program

Building 1- room 1405

665 Huntington Avenue

Boston, MA 02115

(office) 617-432-3326

(fax) 617-432-0219

(e-mail) rhauser@hohp.harvard.edu

Running title: Variability of urinary phthalates.

Key words: Biomarkers, human, phthalates, reliability, urine.

Acknowledgments:

The authors thank Dr. J. Reidy, Ms. A. Herbert, Ms. E. Samandar, and Mr. J. Preau from the CDC and Dr. S. Duty, Ms. J. Frelich, Ms. L. Godfrey-Bailey, Ms. A. Trisini and Mr. R. Dadd from HSPH.

Supported by grant numbers ES09718 and ES00002 from the National Institute of Environmental Health Sciences (NIEHS), NIH. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIEHS.

Abbreviations:

BBzP:	Butyl benzyl phthalate.
CDC:	Centers for Disease Control and Prevention.
DBP:	Di-n-butyl phthalate.
DEHP:	Di-2-ethylhexyl phthalate.
DEP:	Di-ethyl phthalate.
HSPH:	Harvard School of Public Health.
ICCs:	Intra-class correlation coefficients.
LOD:	Limit of detection.
MBP:	Mono-butyl phthalate.
MBzP:	Mono-benzyl phthalate.
MCHP:	Monocyclohexyl phthalate.
MEHP:	Mono-2-ethylhexyl phthalate.
MEP:	Mono-ethyl phthalate.

MGH:	Massachusetts General Hospital.
MINP:	Mono-3-methyl-5-dimethylhexyl phthalate.
MMP:	Mono-methyl phthalate.
MOP:	Mono-n-octyl phthalate.
PVC:	Polyvinyl chloride.
SAS:	Statistical Analysis Software.
µg/L:	Micrograms per liter.

OUTLINE

ABSTRACT

INTRODUCTION

METHODS

STATISTICAL ANALYSES

RESULTS

DISCUSSION

REFERENCES

TABLES 1-4

FIGURES 1-5

Abstract

Phthalates are a family of multifunctional chemicals widely used in personal care and other consumer products. The ubiquitous use of phthalates results in human exposure through multiple sources and routes, including dietary ingestion, dermal absorption, inhalation, as well as through parenteral exposure from medical devices containing phthalates. We explored the temporal variability over three-months in urinary phthalate metabolite levels among eleven men who collected up to nine urine samples each during this time period. Eight phthalate metabolites were measured by solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. Statistical analyses were performed to determine the between- and within-subject variance apportionment, and the sensitivity and specificity of a single urine sample to classify a subject's long-term average exposure. Five of the eight phthalates were frequently detected. Mono-ethyl phthalate (MEP) was detected in 100 percent of samples; mono-butyl phthalate, mono-benzyl phthalate, mono-2-ethylhexyl phthalate (MEHP) and mono-methyl phthalate were detected in over 90 percent of samples. Although we found both substantial day-to-day and month-to-month variability in each individual's urinary phthalate metabolite levels, a single urine sample was moderately predictive of each subject's exposure over three months. The sensitivities ranged from 0.56 to 0.74. Both the degree of between- and within-subject variance and the predictive ability of a single urine sample differed among phthalate metabolites. A single urine sample was moderately predictive of 3-month exposure, although the predictive ability varied across phthalate monoesters. In particular, a single urine sample was most predictive for MEP and least predictive for MEHP. These results suggest that the most efficient exposure assessment strategy for a particular study may depend on the phthalates of interest.

INTRODUCTION

Phthalates, diesters of phthalic acid, are a family of multifunctional chemicals that are widely used in personal and consumer products. Phthalates are used to hold color and scent in consumer and personal care products (Koo et al. 2002), as solvents in paints, glue, insect repellents, lubricants and adhesives (ATSDR 2001), as well as to soften a wide range of plastics (Bradbury 1996), including polyvinyl chloride (PVC) used in the manufacture of medical products such as blood and IV bags, as well as dialysate bags and tubing (Nassberger et al. 1987). Di-ethyl phthalate (DEP), di-n-butyl phthalate (DBP), and butyl benzyl phthalate (BBzP) are principally used in personal care products, such as body lotions, gels, shampoos, and deodorants (ATSDR 1995; ATSDR 2001). They also have U.S. Food and Drug Administration approval for uses in food packaging and processing materials that are in contact with food, and as a result they have been found in food (Castle et al. 1990; Page and Lacroix 1995). DBP, BBzP, and di-2-ethylhexyl phthalate (DEHP) are also used in residential building materials such as floorings, paints, carpet backings, adhesives, and wallpaper, and in PVC products such as auto parts and interiors (ATSDR 2001; ATSDR 2002). Although the volatility of phthalates is relatively low, studies have shown that phthalates are present in residential indoor air (Jaakkoala et al. 1999; Rudel et al. 2003).

The ubiquitous use of phthalates results in human exposure via dietary ingestion of foods (such as milk, butter, and meats), dermal absorption of low molecular weight phthalates (e.g., DEP, DBP, BBzP), inhalation of the more volatile phthalates, as well as through parenteral exposure from medical devices containing phthalates (ATSDR 1995; ATSDR 2001; ATSDR 2002). Recently, researchers at the Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, U.S.A.) developed analytical methods for the quantitative detection of phthalate metabolites in urine (Blount et al. 2000). Phthalate monoester metabolites were measured because of potential sample contamination from the parent diesters and because the metabolites are considered the biologically active toxicant (Li et al. 1998; Peck and Albro 1982; Sjoberg et al. 1986). The use of phthalate

metabolites in urine as biomarkers of exposure now allows researchers to accurately measure human exposure to phthalates. These biomarkers represent an integrative measure of phthalate exposure from multiple sources and pathways. Recently, four phthalate metabolites, namely mono-ethyl phthalate (MEP), mono-2-ethylhexyl phthalate (MEHP), mono-butyl phthalate (MBP), and mono-benzyl phthalate (MBzP), were found in the urine samples of more than 75% of approximately 2550 participants of the National Health Nutrition and Examination Survey (NHANES) 1999-2000 (CDC 2003; Silva et al. 2004).

Since humans and other mammals rapidly metabolize phthalate diesters to their respective monoesters, which, in turn, may be further metabolized, phthalates do not bioaccumulate (ATSDR 1995; ATSDR 2002; ATSDR 2001; Peck and Albro 1982). Because biological half-lives of phthalates are on the order of hours, urinary metabolite levels reflect exposures that most likely occurred a day or less preceding the collection of the urine specimen. However, since most health endpoints of interest are likely associated with exposures over time intervals longer than a few days, information on the temporal variability of urinary levels of phthalate metabolites is needed to optimize the design of exposure assessment in epidemiologic studies. Currently there are limited published data on the temporal variability of urinary phthalate monoester metabolites concentrations. A recent study documented good reproducibility of urinary phthalate monoester levels in two first-morning urine specimens collected for two consecutive days; day-to-day intra-class correlation coefficients (ICCs) ranged from 0.5 to 0.8 (Hoppin et al. 2002). Time intervals beyond a couple of days were not explored.

Variability in an individual's exposure to phthalates can result from changes in the use of personal care products, diet, or daily activity patterns, such as time spent in specific microenvironments (i.e., residential, workplace, or other) with ambient phthalate levels. Therefore, characterizing an individual's phthalate exposure is complex and exposure may vary

considerably over short time periods, such as days. Although phthalate biomarkers in urine are available to accurately measure a person's exposure at a single point in time, determining exposure over time intervals of weeks or months will require multiple measurements of phthalate metabolites. Therefore, the present study was designed to explore the temporal variability in urinary phthalate metabolite levels. Our design allowed us to determine between- and within-subject variability in urinary phthalate metabolite levels, as well as apportion the within-person variability into monthly and daily variances. We also explored the sensitivity of a single urine measurement to predict an individual's three-month average exposure. This information can be used for designing exposure assessment strategies for epidemiologic studies and to adjust for measurement error in phthalate exposure.

METHODS

Eleven men from our ongoing study of the relationship between environmental agents and male reproductive health agreed to participate in the phthalate variability study. Participant recruitment into the environmental agents and male reproductive health study has been previously described (Hauser et al. 2003). Briefly, men who were the partner of couples seeking fertility evaluation for inability to conceive were recruited to participate. The study site was the Massachusetts General Hospital (MGH) Andrology Laboratory and therefore most men resided in the New England area. At the clinic visit, each man was asked to produce a single semen sample and to collect a single spot urine sample.

For each of the eleven men in the phthalate temporal variability study, up to nine additional spot urine samples were collected during three cycles over a 92-day period. Ten of these eleven men contributed a total of up to 10 urine samples (nine for the variability study and one for the male reproductive study), while one of the men provided a total of seven samples (including six for the variability study). Nested within each of the three cycles were three urine samples, collected on the first three consecutive days of each cycle. The first cycle began upon enrollment into the phthalate temporal variability study and urine samples were collected on days 0, 1, and 2. Cycles 2 and 3 began thirty days and ninety days after cycle 1, respectively. Therefore, the nine urine samples were collected on days 0, 1 and 2 (cycle 1); days 30, 31, and 32 (cycle 2); and days 90, 91, and 92 (cycle 3).

All of the urine samples were collected in a sterile specimen cup. The urine sample on day 0 was collected at the MGH Andrology laboratory. All other samples were collected at the subject's home and frozen prior to overnight shipment to the Harvard School of Public Health (HSPH) on blue ice. All urine samples were then shipped frozen on dry ice from HSPH to CDC. Eight phthalate monoesters, mono-benzyl phthalate (MBzP), mono-butyl phthalate (MBP),

mono-ethyl phthalate (MEP), mono-2-ethylhexyl phthalate (MEHP), mono-methyl phthalate (MMP), mono-n-octyl phthalate (MOP), mono-3-methyl-5-dimethylhexyl phthalate (MINP), and monocyclohexyl phthalate (MCHP), were measured in each spot urine sample using an analytical approach developed at CDC (Silva et al. 2003). Briefly, the determination of phthalate metabolites in urine involved enzymatic deconjugation of the glucuronidated metabolites, solid-phase extraction, separation with high performance liquid chromatography, and detection by tandem mass spectrometry. Detection limits were in the low micrograms per liter ($\mu\text{g/L}$) range. Reagent blanks and $^{13}\text{C}_4$ -labeled internal standards were used along with conjugated internal standards to increase the precision of the measurements. One method blank, two quality control samples (human urine spiked with phthalates), and two sets of standards were analyzed along with every twenty-one unknown urine samples. Analysts at the CDC were blind to all information concerning subjects.

There are several methods to adjust for urine volume (Boeniger et al., 1993; Teass et al., 1998). Although creatinine is a frequently used form of adjustment, if a compound is excreted primarily by tubular secretion it is not appropriate to adjust for creatinine level (Teass et al., 1998). Although the methods of excretion of the phthalate monoesters measured in this study are unknown, terephthalic acid was found to be actively secreted by renal tubules and actively reabsorbed by the kidney (Tremaine and Quebbemann, 1985). Furthermore, since organic compounds that are glucuronidated in the liver, like the phthalates, are eliminated by active tubular secretion (Boeniger et al., 1993), creatinine adjustment may not be appropriate for phthalates. Additionally, creatinine levels may be confounded by muscularity, physical activity, urine flow, time of day, diet and disease states (Boeniger et al., 1993; Teass et al., 1998). For these reasons, specific gravity, rather than creatinine, was used to normalize phthalate levels.

Urinary phthalate levels were normalized for dilution by specific gravity adjustment using the following formula: $P_c = P \times [(1.024-1)/(SG-1)]$ where P_c is the specific gravity corrected phthalate concentration ($\mu\text{g/L}$), P is the observed phthalate concentration ($\mu\text{g/L}$) and SG is the specific gravity of the urine sample (Boeniger et al. 1993; Teass et al. 1998). Specific gravity was measured using a handheld refractometer (National Instrument Company, Inc., Baltimore, MD, U.S.A.), which was calibrated with deionized water before each measurement.

Statistical Analyses

We performed the statistical analyses using the Statistical Analysis Software (SAS), version 8.1 (SAS Institute, Cary, NC, U.S.A.). Both unadjusted and specific gravity adjusted values were used. For values below the limit of detection (LOD), corresponding to 1.2 $\mu\text{g/L}$ (MEP), 0.94 $\mu\text{g/L}$ (MBP), 0.47 $\mu\text{g/L}$ (MBzP), 0.86 $\mu\text{g/L}$ (MEHP), 0.70 $\mu\text{g/L}$ (MMP), 0.77 $\mu\text{g/L}$ (MOP), 0.79 $\mu\text{g/L}$ (MINP), and 0.93 $\mu\text{g/L}$ (MCHP), we used an imputed value equal to one-half the LOD.

Graphs were constructed to compare metabolite levels within- and between-subjects.

Spearman correlation coefficients were calculated to investigate correlations between samples collected at different time points.

To assess between- and within-person variability of metabolite levels, ICCs were calculated for each metabolite based on output from a random effects model fit using PROC MIXED (Rosner 1999). ICC, defined as the ratio of between-person variance to total variance, is a measure of reliability of repeated measures over time. ICC ranges from 0 to 1, with values near 1 indicating high reliability and values near 0 indicating poor reliability. ICC can also be used in an internal validity study to account for measurement error in epidemiology effect estimates (Carroll et al. 1995, Rosner et al. 1992).

To apportion variances among nested components, a hierarchical model was fit (using PROC MIXED). For a more robust estimate of between-subject variability, the results of the single urine samples collected from all 369 men enrolled so far in the ongoing environmental agents and male reproductive health study were used in the variance apportionment analysis. Since the eleven men in this variability study were also enrolled in the male reproductive health study, their single urine sample collected for the reproductive study contributed additional information on variability. Within-subject variance was further apportioned into cycle-to-cycle variance and day-to-day variance (Box 1978). Day-to-day variance was defined as the variance in phthalate metabolite levels between samples one or two days apart, regardless of whether they were collected in cycle 1, 2 or 3. Cycle-to-cycle variance was defined as the variance between the three cycles, less the day-to-day variances within the cycles. Since day is nested within cycle, the cycle-to-cycle variance uses information from the three nested daily samples in cycles 1, 2 and 3.

Although ICC is an indicator of reliability for continuous measures, it does not measure the extent of exposure misclassification that may occur if exposure is categorized into tertiles of low, medium and high exposure. To explore categorical exposure misclassification, sensitivity and specificity analyses, as well as surrogate category analyses were performed. In both analyses, tertiles were created using the mean of the nine repeat urine samples for each of the ten subjects in the variability study. The subject with only six repeat urine samples was not included in these analyses since he did not have complete data. Tertiles based on the 369 single urine samples from subjects in the male reproductive health study produced an unbalanced and unstable design since some of these tertiles contained zero subjects from the variability study. This led to non-identifiable results for that tertile. Therefore, analyses using tertiles based on the 369 single urine samples are not presented.

In the surrogate category analysis, actual values for surrogate categories were calculated to show the quantitative differences in phthalate metabolite levels that correspond to the relative categories defined by a single urine sample from the 10 variability subjects (Willett 1998). Variability subjects were first grouped into tertiles by treating each of the nine repeat urines as a single spot urine sample (i.e., the surrogate method). For instance, for each of the nine repeat urine samples, the ten subjects were categorized into high, medium or low tertiles. The “true value” for these same subjects based on their three-month average phthalate metabolite levels (using all the 9 replicate samples) was then assigned to the tertiles defined by the single (surrogate) sample. Each of the nine samples was used as the surrogate sample in separate calculations to check for consistency. Each subject’s tenth sample from the male reproductive health study was not used in this analysis since this sample could have been collected up to 12 months earlier.

Sensitivity and specificity of a single urine sample as a predictor of high and low tertiles of 3-month average phthalate metabolite levels were also evaluated by comparing the distribution of predicted and observed levels for agreement. For observed or “true” exposure, three-month average metabolite levels (using all the 9 replicate samples) were calculated for each subject and the 10 subjects were divided into tertiles. The distribution of 96 individual samples (ten subjects providing 9 replicate samples, one subject providing 6) was then also divided into tertiles, with each sample representing a predicted value based on a single spot urine sample. For each sample time (days 0 to 92), agreement between predicted and observed “true” tertile categorization was scored across all subjects, resulting in nine separate contingency tables. All nine tables were then combined into a single table, where overall sensitivity and specificity was calculated (Peck et al. 2003). The same method was used to assess the sensitivity and specificity if two samples, and then additionally if three samples were taken for each subject at least one cycle apart within a ninety two day time period. When evaluating the sensitivity of two

and three samples, all possible combinations of sample pairings from the nine repeated samples, excluding samples from the same cycle, were used in the analysis. The goal was to simulate and compare the ability of exposure assessments that involve 1, 2, or 3 urine samples to predict a subject's "true" 3-month average exposure tertile classification.

RESULTS

Eight phthalate metabolites were measured in urine. However, since more than 75 percent of the samples had non-detectable levels of MCHP, MOP and MINP, the results for these three metabolites were not informative and were not included in the analyses. MEP was detected in 100 percent of samples, while MBP, MBzP, MEHP, and MMP were detected in over 90 percent of samples.

Unadjusted and specific gravity adjusted median concentrations of MEP, MBP, MBzP, MEHP and MMP from the 369 men who provided a single urine sample for the environmental agents and male reproductive health study are presented in Table 1. Of these 369 men, eleven also participated in the variability study. Ten of the eleven men provided nine urine samples collected over ninety-two days, while one man collected six urine samples over thirty-two days only. In Figures 1 - 5, the unadjusted (Panel A) and specific gravity adjusted (Panel B) urinary phthalate metabolite concentrations are plotted by day for each subject (the one subject with only six urine samples was not plotted). Even after dilution adjustment, there was still substantial variability in phthalate metabolite concentrations over time. MEHP concentrations showed large within-subject variability, while MEP showed less within-subject variability.

Spearman correlation coefficients confirmed that urine samples taken closer together in time (days apart) were more strongly correlated than those collected months apart. The between- and within-subject variance apportionments for specific gravity adjusted phthalate levels are shown in Table 2. Within-subject variance was then apportioned into cycle-to-cycle and day-to-day variance. As expected, the standard errors of the between-subject variance component estimates remained the same or were reduced when the single samples from the 358 men participants in the environmental agents and male reproductive health study were included in the analysis. The single urine samples contributed more information on between-subject than

within-subject variability. The between-subject variance estimates increased for all phthalate monoesters except for MMP and MEP. Between-subject variances ranged from 27.4% for MMP to 71.3% for MBP; therefore ICC ranged from 0.27 for MMP to 0.71 for MBP.

Of the total subject variance among the 369 subjects, the day-to-day variance component ranged from 27.2% (MBP) to 58.1% (MMP), while the cycle-to-cycle variances ranged from 1.5% (MBP) to 16.3% (MEP). Cycle-to-cycle variance is the within-subject variance remaining after day-to-day variance is calculated using the replicate samples nested within each of the 3 cycles. These results suggest that after accounting for day-to-day variance there is little additional cycle-to-cycle variance. Therefore, if we were to collect only two urine samples a day apart, we would account for 83.7% to 98.5%, depending on the phthalate monoester, of the total subject variance which is composed of between- and within-subject day-to-day variance. Likewise, if we collected two urine samples one month apart we would account for both cycle-to-cycle and day-to-day variability, or 100% of the within-subject variance. This is because when collecting two urine samples one month apart, cycle-to-cycle variance is a composite of both day-to-day and cycle-to-cycle variance.

To determine the predictive ability of a single urine sample to correctly categorize a subject's exposure into high, medium or low tertiles, actual values (mean and geometric mean values) for surrogate categories were calculated. The results are presented in Table 3 (only the ten subjects who provided 9 urine samples each were used in this analysis). Overall, the results suggest that a single spot urine sample was predictive of the three-month average exposure since there were monotonic increasing geometric means across tertiles. For instance, for MBP when a single sample on Day 0 was used to group subjects into low, medium and high exposure groups, the 'true' geometric mean MBP levels increased from 12.66 µg/L in the group designated as low exposure, to 22.80 µg/L in the medium exposure group, to 28.26 µg/L in the

high exposure group. Although single spot urine samples were generally predictive, there were differences in the predictive ability of a single urine sample for different phthalate monoesters. A single urine sample was least predictive for MEHP where only five of the nine spot urine samples produced a monotonic increasing geometric mean. In contrast, eight of the nine spot urine samples produced monotonic increasing geometric means for MBzP, MBP, MEP and MMP. As expected, MEP, with the widest range in exposure levels, showed the largest difference in geometric means between low, medium and high exposure categories.

For a more quantitative assessment of how well a single urine sample predicts a subject's exposure category based on three-month average metabolite levels, a sensitivity and specificity analysis, using only the results from the ten subjects who provided 9 urine samples each, was conducted (Table 4). The proportion of men that truly had the highest 3-month average exposure (top 33 percent) that would be identified as such using single urine samples anytime throughout that 3-month period (i.e., sensitivity) ranged from 0.56 for MEHP to 0.74 for MMP. The proportion of men with truly comparatively low exposure (tertiles 2 and 3) that were classified correctly (i.e., specificity) ranged from 0.83 for MEHP to 0.90 for MMP. Sensitivity analyses for one, two or three urine samples are presented in Table 4. When two samples were collected one to three months apart, there were small increases in sensitivity and specificity, especially evident for MEHP. When three urine samples were collected, each one to three months apart, sensitivity moderately increased for MEHP and MMP, with slight increases for the other monoesters. In contrast, when three urine samples were collected on three consecutive days, sensitivity for MEHP, MBzP, MBP and MMP did not increase. However, sensitivity did increase for MEP.

All analyses described above were also performed using unadjusted phthalate levels (data not shown). Overall, variance apportionment and sensitivity analyses were very similar to the

specific gravity adjusted results shown above. The surrogate exposure category method differed slightly with less consistent dose-response categories found for the unadjusted phthalate metabolite levels.

DISCUSSION

Although the present study found substantial within-subject variability in urinary phthalate metabolite levels, the sensitivity of a single spot urine sample to predict 3-month average phthalate exposure was moderate to high. As expected, since phthalates are rapidly metabolized and do not bioaccumulate, the collection of additional urine samples, one to three months apart improves the prediction of a subject's 3-month average exposure. The levels of urinary metabolite levels found in the present study were similar to reference ranges measured in U.S. males for NHANES 1999-2000 (CDC 2003; Silva et al. 2004).

The predictive ability of a single urine sample to determine a subject's 3-month average exposure varied across phthalates. For MEHP, a single urine sample was least predictive of the tertile categorization and had the lowest sensitivity (Table 4). This implies that in statistical analyses in which only a single urine sample is available to categorize a subject's three-month exposure to MEHP, there is likely exposure measure misclassification resulting in bias towards the null hypothesis for exposure-response relationships. MEHP has been associated with developmental reproductive toxicity in laboratory studies (Oishi 1986; Park et al. 2002; Sjoberg et al. 1986). However, in our previously published study, we did not find an association between MEHP and semen parameters among adult men (Duty et al. 2003). In contrast, we did find associations between MBP and MBzP with semen parameters. Although our study differed from the animal studies since we measured adult and not gestational exposure, our findings suggesting that a single urine sample, used to categorize a subjects' exposure, did not adequately measure 3-month average exposure to MEHP. This may partially explain our inability to detect associations between semen parameters with MEHP. To improve upon our exposure classification of MEHP, we are currently collecting two urine samples one month apart from all subjects. This will allow us to use measurement error correction methods to adjust for exposure misclassification of phthalate exposure (Carroll et al. 1995).

It is possible the calculated sensitivities and specificities may be slightly overestimated to a small degree because we included predicted values in the calculation of the observed values. Therefore, the errors of predicted and observed values are not totally independent, which can lead to an overestimation of sensitivity and specificity (Willett 1998). Similarly, a portion of the increased sensitivity and specificity observed when taking two or three samples per subject instead of a single sample may be partly due to the increased dependence between the errors of the predicted and observed values.

Apportioning the sources of variability in urinary phthalate metabolite levels can be used to design more valid and efficient exposure assessments. As expected, the urinary phthalate metabolite concentrations in samples collected close together in time, separated by one to two days, were more correlated than those in samples collected further apart in time, separated by one to three months. Two samples collected a month or more apart include variability in urinary phthalate metabolite levels contributed to by both day-to-day changes in exposure as well as factors contributing to monthly trends in phthalate exposure, such as seasonal changes in diet, personal product use or activity patterns, as well as other environmental or biological factors.

For each health endpoint of interest in an epidemiologic study, the relevant time window over which exposure is measured needs to be defined. For acute responses following acute exposures, a single urine sample may be adequate to define phthalate exposure. However, we are generally interested in health endpoints that have exposure windows of months, if not years. To this end, accurate exposure assessment depends on a strategy whereby we accurately measure exposure over these time windows. The simplest approach is to collect multiple urine samples from all subjects over the time interval of interest. However, it is not always feasible to collect multiple urine samples due to both cost constraints and limitations imposed by the

subject's commitments to multiple collections. Based on the results of this variability study, for male reproductive health endpoints, we recommend collecting at least two urine samples one to three months apart. This will provide an estimate of the within-person variability taking into account both month-to-month and day-to-day variance. Nevertheless, if the study design only permitted collecting two samples one to two days apart, this too would provide a reasonable estimate of within-subject variance contributed to by day-to-day variance. Having collected the replicate urine samples in either sampling scheme, measurement error models could then be used to adjust for measurement error in exposure (Carroll et al. 1995). A discussion of this is beyond the scope of this report.

In conclusion, although a single urine sample was moderately predictive of 3-month exposure to phthalates, the predictive ability varied across phthalate monoesters. A single urine sample was most predictive for MEP and least predictive for MEHP. The single sample performed well in classifying subject's exposure into tertiles and the amount of non-differential random exposure misclassification is likely to be moderate or small for most phthalate metabolites of interest. The variance apportionment analysis suggests that two urine samples, the second collected one to three months after the first sample, is the minimum number of samples necessary to account for the within subject day-to-day and cycle-to-cycle variability in urinary phthalate metabolite levels. Since the degree of between- and within-subject variance and thus the predictive ability of a single urine sample differ between phthalate metabolites, the most efficient exposure assessment strategy for a particular study depends on the phthalates of interest. The results from the present study will be used in our ongoing environmental agents and male reproductive health study to correct for measurement error in the effect estimates of exposure-response relationships between phthalates and sperm function. The findings from this variability study may also be pertinent to other endpoints with relevant exposure periods of several months. However, if the study population is not adult men of reproductive age, such as studies involving

children or pregnant women, we recommend that a variability study be conducted to determine population specific exposure assessment strategies.

References

ATSDR. 1995. Toxicological Profile for Diethyl phthalate (DEP). Atlanta, GA:U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. Available: <http://www.atsdr.cdc.gov/toxprofiles>.

ATSDR. 2002. Toxicological Profile for Di(2-ethylhexyl)phthalate (DEHP). Atlanta, GA:U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. Available: <http://www.atsdr.cdc.gov/toxprofiles>.

ATSDR. 2001. Toxicological Profile for Di-n-butyl phthalate (DBP). Atlanta, GA:U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry. Available: <http://www.atsdr.cdc.gov/toxprofiles>.

Blount BC, Milgram KE, Silva MJ, Malek NA, Reidy JA, Needham LL, et al. 2000. Quantitative detection of eight phthalate metabolites in human urine using HPLC-APCI-MS/MS. *Anal Chem* 72:4127-34.

Boeniger MF, Lowry LK, Rosenberg J. 1993. Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: A review. *J Amer Ind Hyg Assoc* 54:615-627.

Box GE, Hunter WG, Hunter JS. 1978. Statistics for Experimenters. New York, John Wiley & Sons.

Bradbury J. 1996. UK panics over phthalates in babymilk formulae. *Lancet* 347:1541.

Carroll RJ, Ruppert D, Stefanski LA. 1995. Measurement Error in Nonlinear Models. New York: CRC Press.

Castle L, Jickells SM, Gilbert J, Harrison N. 1990. Migration testing of plastics and microwave-active materials for high-temperature food-use applications. *Food Addit Contamin* 7:779-796.

CDC. 2003. "Second National Report on Human Exposure to Environmental Chemicals." Washington, DC. Centers for Disease Control and Prevention. Available: <http://www.cdc.gov/exposurereport/reportresults.htm> [accessed 15 March 2003].

Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen Z, et al. 2003a. The relationship between environmental exposure to phthalates and human semen parameters. *Epidemiology* 14:269-277.

Duty SM, Singh NP, Silva MJ, Barr DB, Brock JW, Ryan L, et al. 2003b. The relationship between environmental exposure to phthalates and DNA damage in human sperm using the neutral comet assay. *Environ Health Perspect* 111:1164-1169.

Hauser R, Chen Z, Pothier L, Ryan L, Altshul L. 2003. The relationship between human semen parameters and environmental exposure to polychlorinated biphenyls and p,p'-DDE. *Environ Health Perspect* 111:1505-11.

Hoppin JA, Brock JW, Davis BJ, Baird DD. 2002. Reproducibility of urinary phthalate metabolites in first morning urine samples. *Environ Health Perspect* 110:515-518.

Jaakkoala JJ, Oie L, Nafstad P, Botten G, Samuelsen SO, Magnus P. 1999. Interior surface materials in the home and the development of bronchial obstruction in young children in Oslo, Norway. *Am J Public Health* 2:188-191.

Koo J-W, Parham F, Kohn MC, Masten SA, Brock JW, Needham LL, et al. 2002. The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population. *Environ Health Perspect* 110:405-410.

Li L-H, Jester WF, Orth JM. 1998. Effects of relatively low levels of mono-(2-ethylhexyl) phthalate on cocultured sertoli cells and gonocytes from neonatal rats. *Toxicol Appl Pharmacol* 153:258-265.

Nassberger L, Arbin A, Ostelius J. 1987. Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis. *Nephron* 45:286-290.

Oishi S. 1986. Testicular atrophy induced by di(2-ethylhexyl)phthalate: changes in histology, cell specific enzymes and zinc concentrations in rat testis. *Arch Toxicol* 59(4):290-295.

Page BD, Lacroix GM. 1995. The occurrence of phthalate esters and di-2-ethylhexyl adipate plasticizers in a Canadian packaging and food samples in 1985-1989: a survey. *Food Addit Contam* 12:129-151.

Park JD, Habeebu SSM, Klaassen CD. 2002. Testicular toxicity of di-(2-ethylhexyl)phthalate in young Sprague-Dawley rats. *Toxicology* 171:105-115.

Peck CC, Albro PW. 1982. Toxic potential for the plasticizer di(2-ethylhexyl) phthalate in the

context of its disposition and metabolism in primates and man. *Environ Health Perspect* 45:11-17.

Peck JD, Hulka BS, Savitz DA, Baird D, Poole C, Richardson BE. 2003. Accuracy of fetal growth indicators as surrogate measures of steroid hormone levels during pregnancy. *Am J Epidemiol* 157:258-66.

Rosner BD, Spiegelman D, Willett WC. 1992. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. *Am J Epidemiol* 136(11):1400-13.

Rosner B. 1999. *Fundamentals of Biostatistics*. Pacific Grove, CA, Duxbury Press.

Rudel RA, Camann DE, Spengler JD, Korn LR, Brody JG. 2003. Phthalates, alkylphenols, pesticides, polybrominated diphenyl ethers, and other endocrine-disrupting compounds in indoor air and dust. *Environ Sci Technol* 37(20):4543-4553.

Silva MJ, Malek NA, Hodge CC, Reidy JA, Kato K, Barr DB, et al. 2003. Improved quantitative detection of 11 urinary phthalate metabolites in humans using liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry. *J Chromatog B* 789:393-404.

Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, et al. 2004. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. *Environ Health Perspect* 112:331-338.

Sjoberg P, Lindquist NG, Ploen L. 1986. Age-dependent response of the rat testis to di-2-(ethylhexyl) phthalate. *Environ Health Perspect* 65:237-242.

Teass AW, Biagini RE, DeBord G, Hull RD. 1998. Application of biological monitoring methods. In: *NIOSH Manual of analytical method* (Eller PM, ed). Cincinnati:U.S. Dept. of Health and Human Service, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health , Division of Physical Sciences and Engineering, 52-62.

Tremaine LM, Quebbemann AJ. The renal handling of terephthalic acid. *Toxicol Appl Pharmacol* 1985; 77:165-174.

Willett W. 1998. *Nutritional Epidemiology*. New York, Oxford University Press.

Table 1. Distribution of phthalate metabolite levels measured in a single spot urine sample from 369 men, in µg/L.

Phthalate Metabolite	Geometric Mean	Selected Percentiles					
		10th	25th	50th	75th	90th	95th
Unadjusted							
MEHP	5.68	0.49	1.90	5.20	17.2	63.6	110.2
MBzP	5.57	1.10	2.40	6.00	13.7	25.3	34.7
MEP	148.5	22.7	46.1	128.2	443.7	1144	1879
MBP	13.3	2.89	7.00	13.6	29.3	50.4	73.1
MMP	3.84	0.36	1.70	4.37	9.61	21.5	29.9
SG-adjusted							
MEHP	6.75	0.80	2.40	6.52	19.5	64.5	119.9
MBzP	6.61	1.75	3.84	7.20	14.0	22.8	36.2
MEP	175.1	30.7	58.7	153.1	495.1	1145	1897
MBP	15.8	4.76	9.84	16.0	29.2	45.9	66.7
MMP	4.54	0.61	2.18	4.86	11.7	22.4	30.4

Abbreviations: Mono-2-ethylhexyl phthalate (MEHP), mono-benzyl phthalate (MBzP), mono-ethyl phthalate (MEP), mono-butyl phthalate (MBP), mono-methyl phthalate (MMP).

Table 2. Variance apportionment for specific gravity-corrected phthalate levels in urine

	Variability Subjects Only, N=11, n=96			All Subjects ^a, N=369, n=465		
	Variance	Std. Error of	% of Total	Variance	Std. Error of	% of Total
	Estimate	Variance	Variance	Estimate	Variance	Variance
In(MEHP)						
Subject ^b	0.49	0.32	27.9	1.57	0.31	54.3
Cycle ^c	0.30	0.20	17.3	0.33	0.21	11.4
Day ^d	0.97	0.17	54.7	0.99	0.18	34.3
In(MBzP)						
Subject	0.47	0.25	42.5	0.80	0.14	55.1
Cycle	0.075	0.086	6.9	0.083	0.09	5.7
Day	0.54	0.096	50.5	0.57	30.10	39.2
In(MEP)						
Subject	1.08	0.59	46.2	0.87	0.19	42.9
Cycle	0.33	0.20	14.5	0.33	0.16	16.3
Day	0.89	0.16	39.3	0.83	0.13	0.9
In(MBP)						
Subject	0.14	0.085	29.0	0.84	0.10	71.3
Cycle	0.025	0.046	5.0	0.018	0.041	1.5
Day	0.33	0.058	66.0	0.32	0.059	27.2
In(MMP)						
Subject	1.11	0.55	51.7	0.51	0.21	27.4
Cycle	0.011	0.12	0.5	0.27	0.25	14.5
Day	1.03	0.18	47.8	1.08	0.19	58.1

Abbreviations: N=number of subjects; n=number of samples; mono-2-ethylhexyl phthalate, MEHP; mono-benzyl phthalate, MBzP; mono-ethyl phthalate, MEP; mono-butyl phthalate, MBP; mono-methyl phthalate, MMP.

^a All subjects includes ten variability subjects who provided 10 samples each, one subject who provided 7 samples, plus 358 subjects who provided a single sample

^b Subject=between-subject variance

^c Cycle=variance between three cycles after accounting for nested day-to-day variance

^d Day=variance between three consecutive days within a cycle

Table 3. Values for surrogate exposure categories comparing a single urine sample with 3-month average levels based on nine replicates from 10 men.

Surrogate	Mean (µg/L)			Geometric Mean (µg/L)		
	Low	Med	High	Low	Med	High
MEHP						
Day0	19.94	28.85	44.67	9.26	11.53	18.30
Day1	9.48	55.65	19.40	5.13	26.33	10.99
Day2	18.83	26.22	49.27	7.06	11.11	25.22
Day30	5.59	44.92	37.59	4.40	24.31	14.23
Day31	5.59	43.83	39.04	4.40	20.06	18.40
Day32	23.61	23.15	48.60	11.23	9.17	20.49
Day90	10.02	29.69	53.47	5.01	12.65	29.90
Day91	9.48	30.05	53.52	5.13	14.31	24.77
Day92	10.19	31.06	51.47	6.07	11.68	27.46
MBzP						
Day0	4.88	11.23	14.25	3.11	7.50	13.18
Day1	6.56	9.25	15.20	2.94	7.76	13.34
Day2	7.84	9.17	14.03	4.33	5.99	12.80
Day30	6.33	11.19	12.84	3.93	8.49	8.86
Day31	6.56	10.13	14.03	2.94	8.01	12.80
Day32	7.21	10.09	13.44	3.48	7.48	11.85
Day90	8.33	11.07	11.01	4.21	7.81	9.23
Day91	8.02	9.87	12.91	3.71	7.77	10.57
Day92	7.21	9.87	13.73	3.48	7.77	11.28
MEP						
Day0	73.15	158.41	171.69	28.89	46.75	94.42

Day1	26.61	199.64	163.25	15.80	98.30	64.09
Day2	30.24	112.57	275.72	6.22	70.19	97.83
Day30	145.85	92.83	186.43	24.39	39.74	138.91
Day31	26.61	103.89	290.93	15.80	53.08	145.74
Day32	26.61	182.26	186.43	15.80	55.03	138.91
Day90	30.24	157.67	215.60	16.22	50.16	153.12
Day91	33.38	155.31	215.60	15.98	50.73	153.12
Day92	63.88	132.44	215.60	20.29	42.40	153.12

MBP

Day0	16.32	30.31	30.52	12.66	22.80	28.26
Day1	16.74	24.89	37.33	13.10	21.61	29.33
Day2	16.74	26.29	35.46	13.10	20.51	31.44
Day30	17.99	23.37	38.11	13.51	18.63	34.66
Day31	16.32	27.70	34.00	12.66	22.65	28.52
Day32	16.74	27.70	33.58	13.10	22.65	27.56
Day90	26.35	24.38	28.40	19.77	21.64	19.40
Day91	21.73	21.95	36.26	14.38	18.74	32.32
Day92	21.31	26.57	30.52	13.90	21.26	28.26

MMP

Day0	4.19	7.92	30.22	2.01	5.56	23.19
Day1	4.06	9.44	28.33	2.41	5.17	21.30
Day2	4.99	7.32	30.22	4.08	3.27	23.19
Day30	3.90	8.14	30.22	2.14	5.29	23.19
Day31	4.32	9.24	28.33	2.49	5.04	21.30
Day32	4.86	11.52	24.76	3.28	5.71	13.65
Day90	4.19	12.40	24.26	2.01	6.23	19.90
Day91	4.32	12.30	24.26	2.49	5.30	19.90

Day92	4.01	12.54	24.26	2.21	5.80	19.90
-------	------	-------	-------	------	------	-------

Note: Only the ten subjects who provided 9 urine samples each were used in this analysis.

Abbreviations: mono-2-ethylhexyl phthalate, MEHP; mono-benzyl phthalate, MBzP; mono-ethyl phthalate, MEP; mono-butyl phthalate, MBP; mono-methyl phthalate, MMP.

Table 4. Sensitivity and specificity for predicting men with highest 3-month average phthalate levels (top 33%) with one, two or three urine samples (N=10 men, 90 samples)

	MEHP		MBzP		MEP		MBP		MMP	
	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity	Sensitivity	Specificity
One Sample	0.56	0.83	0.63	0.84	0.63	0.87	0.67	0.87	0.74	0.90
					(0.67) ^a	(0.86)				
Two Samples	0.63	0.84	0.65	0.85	0.69	0.88	0.65	0.85	0.81	0.92
(at least 1					(0.78)	(0.90)				
month apart)										
Three Samples	0.73	0.88	0.69	0.87	0.68	0.88	0.68	0.86	0.90	0.96
(at least 1					(0.70)	(0.87)				
month apart)										
Three Samples	0.56	0.81	0.67	0.86	0.78	0.90	0.67	0.86	0.78	0.90
(3 consecutive					(0.67)	(0.90)				
days)										

Note: Only the ten subjects who provided 9 urine samples each were used in this analysis.

Abbreviations: mono-2-ethylhexyl phthalate, MEHP; mono-benzyl phthalate, MBzP; mono-ethyl phthalate, MEP; mono-butyl phthalate, MBP; mono-methyl phthalate, MMP.

^a Sensitivity and specificity using geometric mean ranks instead of arithmetic mean ranks for observed tertile classification. For the other 4 phthalates these values were identical.

Figure 1a. Nine repeated urine samples collected from 10 men over a 3-month period.
MEHP unadjusted.

Figure 1b. Nine repeated urine samples collected from 10 men over a 3-month period.
MEHP specific-gravity adjusted.

Figure 2a. Nine repeated urine samples collected from 10 men over a 3-month period.
MBzP unadjusted.

Figure 2b. Nine repeated urine samples collected from 10 men over a 3-month period.

MBzP specific-gravity adjusted

Figure 3a. Nine repeated urine samples collected from 10 men over a 3-month period. MEP unadjusted.

Figure 3b. Nine repeated urine samples collected from 10 men over a 3-month period. MEP specific-gravity adjusted.

Figure 4a. Nine repeated urine samples collected from 10 men over a 3-month period. MBP unadjusted.


Figure 4b. Nine repeated urine samples collected from 10 men over a 3-month period. MBP specific-gravity adjusted.


Figure 5a. Nine repeated urine samples collected from 10 men over a 3-month period. MMP unadjusted.


Figure 5b. Nine repeated urine samples collected from 10 men over a 3-month period. MMP specific-gravity adjusted.


1 A

MEHP




1 B**MEHP**

2 A**MBZP**

2 B**MBZP**


3 A

MEP




3 B


MEF



4 A


MBP



4 B**MBP**

5 A

MMP



5 B**MMP**